Northern Trust Corp Has $768.55 Million Holdings in Becton Dickinson and Co (NYSE:BDX)
Northern Trust Corp cut its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 3.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,208,183 shares of the medical instruments supplier’s stock after selling 111,346 shares during the quarter. Northern Trust Corp owned about 1.20% of Becton Dickinson and worth $768,552,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in BDX. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson and in the 2nd quarter valued at about $105,000. Bartlett & Co. LLC raised its position in Becton Dickinson and by 2,900.0% in the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 435 shares in the last quarter. Bridgeworth LLC acquired a new stake in Becton Dickinson and in the 2nd quarter valued at about $131,000. BDO Wealth Advisors LLC raised its position in Becton Dickinson and by 361.6% in the 1st quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock valued at $125,000 after purchasing an additional 452 shares in the last quarter. Finally, Kaizen Advisory LLC raised its position in Becton Dickinson and by 155.9% in the 2nd quarter. Kaizen Advisory LLC now owns 609 shares of the medical instruments supplier’s stock valued at $146,000 after purchasing an additional 371 shares in the last quarter. Institutional investors own 92.51% of the company’s stock.
A number of equities research analysts have issued reports on BDX shares. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Morgan Stanley raised their target price on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 4th. KeyCorp reissued a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 target price on the stock in a research report on Thursday, June 21st. Finally, Citigroup raised their target price on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $253.79.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.86 by $0.05. The company had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The firm’s revenue was up 41.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.46 earnings per share. Equities analysts expect that Becton Dickinson and Co will post 11.01 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 28th. Shareholders of record on Friday, September 7th were given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.24%. The ex-dividend date was Thursday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is 31.65%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.